📄 SCRIBE THERAPEUTICS, INC.

📄 SCRIBE THERAPEUTICS, INC. Scribe Therapeutics is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies to extend healthy lifespan through disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic diseases, with its lead product candidate STX-1150 designed to durably lower LDL-C via epigenetic silencing without permanent genetic changes. Scribe has initiated a first-in-human clinical trial for STX-1150 and is advancing a pipeline targeting key lipid drivers of atherosclerotic cardiovascular disease. Key risk: Limited operating history with no completed clinical trials or approved products, making evaluation of business success and future viability difficult. Proceeds: Advance development of lead product candidate STX-1150, Advance development of additional product candidates STX-1200 and STX-1400, Continued investment in pipeline programs, CRISPR-based technologies (ELXR and XE), and new techn

Scribe Therapeutics is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies to extend healthy lifespan through disease prevention and durable therapeutic intervention. The company focuses on cardiovascular and metabolic diseases, with its lead product candidate STX-1150 designed to durably lower LDL-C via epigenetic silencing without permanent genetic changes. Scribe has initiated a first-in-human clinical trial for STX-1150 and is advancing a pipeline targeting key lipid drivers of atherosclerotic cardiovascular disease.